Pirfenidone

8 trials 3 recruiting LOncology

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

3 Completed trials

6 Sponsors

10 Countries

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 4 Phase I/II: 1

Indications tested

Idiopathic pulmonary fibrosis 2 Interstitial lung disease 2 Pulmonary fibrosis 1

Sponsors using this IMP

Avalyn Pharma Inc. 3 Dr. Douglas D. Fraser 1 Hospices Civils De Lyon 1 Medical University Of Gdansk 1 Ospedale San Raffaele S.r.l. 1 Puretech Lyt 100 Inc. 1

All trials

8 total

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study Not authorised

2025-522611-42-00 Phase III 1 country Dr. Douglas D. Fraser
PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending

2024-514355-16-01 Phase III 1 country Ospedale San Raffaele S.r.l.
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent Recruiting

2024-518289-28-00 Phase II 7 countries Avalyn Pharma Inc.
A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting

2023-508429-29-00 Phase II 7 countries Avalyn Pharma Inc.
Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseas… Recruiting

2024-514433-38-00 Phase I/II 1 country Medical University Of Gdansk
A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulm… Ended

2024-511330-13-00 Phase II 2 countries Puretech Lyt 100 Inc.
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathi… Ended

2024-515964-30-00 Phase II 3 countries Avalyn Pharma Inc.
Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended

2024-511427-34-00 Phase III 1 country Hospices Civils De Lyon

Showing 1–8 of 8 trials

← All drugs A–Z